SC3: STRUCTURE-BASED OPTIMIZATION OF ANTIBODIES
TUESDAY, JANUARY 21 | 5:45 - 8:45 PM (DINNER PROVIDED)
CHI’s “Structure-Based Optimization of Antibodies” is a 3-hour course that offers a quick overview of the concepts, strategies, and tools of structure-based optimization of antibodies. This lecture will cover structure-based techniques
to modulate affinity, create novel constructs (such as Fc-fusions, bispecifics, etc.) along with increasing the manufacturability of a biologic. The class is directed at scientists new to the industry, academic scientists, and career protein engineers
wanting a quick overview about how structure can aid in guiding experimental design.
5:45 pm Welcome and Opening Remarks
- Basics of Structural Modeling
- What is molecular modeling and where does it fit into drug discovery?
- Modeling 101
- Affinity & Specificity
- Examining interactions & predicting binding affinity/specificity
- Introducing avidity
6:15 Dinner Break
- Engineering Therapeutic Constructs
- Bispecific antibody engineering
- Rational design of Fc-fusion proteins
- ADC design
- Modulation of Biological Functions
- Immune effector functions
- Structure-Based Developability Assessment
- Protein stability (thermal, chemical, and aggregation)
- Immunogenicity and humanization
8:45 Close of Short Course
Traian Sulea, PhD, Principal Research Officer, Human Health Therapeutics, Biotechnology Research Institute, National Research Council Canada
Dr. Traian Sulea is a Principal Research Officer who joined the National Research Council Canada as a post-doctoral fellow in 1995. He is also Adjunct Professor at the Institute of Parasitology of McGill University since 2012. Dr. Sulea has broad expertise
in applying computational approaches to the discovery and optimization of bioactive small-molecules and biologics. He has contributed to the development of computational methods for biomolecular applications, focusing on continuum solvation models
and binding-affinity scoring functions. He has applied structural modeling for bioengineering of growth-factor traps and selective tumor targeting, as well as antibody humanization, conjugation, affinity maturation, de novo design, and developability.
Dr. Sulea has authored 94 scientific articles and book chapters, and is an inventor on 29 patents issued or pending.
Back to Short Courses